Skip to main content

Table 1 Virological analyses, case 1

From: Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy

Days post infection

SARS-CoV-2 PCR

Assay used

Mean CT value

SARS-CoV-2 N Ab (units)

0

Detected

1

23.1

–

15

Detected

1

22.2

–

22

Detected

1

28.4

–

29

Detected

2

26.3

–

36

Detected

2

29.3

–

44

Detected

2

24.1

–

52

–

 

–

Not detected (0.09)

54

Detected

1

28.2

–

55

–

 

–

Detected (2.07)

63

–

 

–

Detected (13.19)

68

Detected

1

27.6

-

79

Detected

1

29.3

Detected (5.74)

87

Detected

1

27.9

–

115

Indeterminate

3

28.5

–

122

Detected

3

26.9

–

136

Detected

2

32.8

Detected (1.17)

150

Detected

2

23.9

Not detected (0.78)

176

Detected

4

–

–

182

Detected

2

32.8

–

185

Detected

2

31.9

–

189

Detected

4

–

–

190

Detected

1

23.5

–

206

Detected

2

31.7

–

208

Detected

1

28.7

–

213

Not detected

1

–

–

215

Not detected

1

–

–

217

-

 

–

Not detected

221

Not detected

2

–

–

228

Not detected

1

–

–

254

Not detected

1

–

–

321

Not detected

2

–

–

  1. PCR assay and gene targets: [Altona RealStar® SARS-CoV-2 RT-PCR Kit 1.0 (S & E); 2. Roche: Cobas® SARS-CoV-2 Test (Orf1a/b & E); 3. Mobiag: Amplidiag® COVID-19 (Orf1a/b & N); 4. DRW: SAMBA II SARS-CoV-2 Test (Orf1a/b & N)]. Antibody assay: [Roche Elecsys Anti-SARS-CoV-2 assay (nucleocapsid). CP was administered on day 54 and REGN-CoV2 at day 207